濮阳东方医院妇科做人流好不好濮阳东方医院男科看早泄很正规,濮阳东方医院治疗早泄口碑很好,濮阳东方男科医院割包皮非常好,濮阳东方医院看妇科比较好,濮阳东方医院看男科病技术值得信赖,濮阳东方男科好不好,濮阳东方医院男科治疗阳痿正规吗

SHANGHAI, Jan. 11 (Xinhua) -- The listed arm of China's biggest train maker, China South Locomotive and Rolling Stock Industry (Group) Corporation (CSR), has been allowed by regulatory authorities to raise 9 billion yuan (1.41 billion U.S. dollars) on the stock market, the company said Wednesday.The Hong Kong- and Shanghai- listed CSR Corp. Ltd. will sell 1.96 billion shares at 4.46 yuan apiece to select investors, it said. But CSR's parent -- state-owned CSR Group -- has agreed to buy no less than 6 billion yuan's worth of the shares, leaving the rest to institutional investors.CSR's net profit growth in the third quarter of 2011 plunged to 9.66 percent year-on-year from a high of 85.08 percent in the first half of 2011 as the country put the brakes on development of the railway sector after a deadly bullet train crash on July 23 that killed 40 people and injured 210 others.The decision to slow the development of high-speed rail lines has led to halts in construction of about 90 percent of ongoing railway projects, or 10,000 km of rail lines across the country, local media reported earlier.CSR is the maker of the bullet trains involved in last July's deadly collision. After the accident, the company's executives bought a combined 540,000 share in August, a move seen as an attempt to bolster battered stock prices.Analysts say the fundraising would help CSR greatly ease its financial burdens. The company earlier pledged to maintain profit growth and its dividend policy to boost investors' confidence.

BEIJING, Oct. 12 (Xinhuanet) -- People are often recommended to eat plenty of fruits and vegetables, but only a minority people take the advice. A new research may motivate more people to do so.BBC reported a new study Tuesday that found eating lots of vegetables and fruits can weaken the effect of a gene variant called 9p21, which is reported to be one of the strongest predictors for heart disease, thereby reducing risks of heart disease.The researchers from McMaster and McGill universities studied the diets of more than 27,000 people around the world, including Europe, China, and Latin America.They found that people with the high-risk gene appeared to have a similar risk of heart disease as people with a low-risk variant of that gene after consuming a diet with a healthy amount of vegetables and fruits.But how diet has such an effect on the gene was unknown, said Dr. Sonia Anand, a lead author of the study published in PLoS Medicine journal.Anand added, "Despite having a high genetic risk for heart disease, a healthy lifestyle can actually turn off the gene."The message here is very clear, eating plenty of vegetables and fruits is definitely good to people's heart health, according to BBC.

BEIJING Jan. 10 (Xinhuanet) -- Scientists have found a plant in Brazil using leaves to capture the tiny worms in the soil, according to Monday's Proceedings of the National Academy of Sciences in the U.S.The plant, named Philcoxia, was found in the tropical grassland of Brazil, where the biodiversity is well conserved.As the scientists searching for the answer of why the plant grows the leaves underground, they found the 1.5 millimeters-wide leaves can trap the worms and produce a digestive enzyme to help its roots to absorb the nutrition.Although it is not the first meat-eating plant to be discovered, the finding has still "broaden up our perception about plants," according to researcher Rafael Silva Oliveira, a plant ecologist at the State University of Campinas in Brazil.It suggests that carnivorous plants "may have evolved independently more times in plants than previously thought," he added

BEIJING, Dec. 16 (Xinhua) -- China issued rules for pilot programs of RMB Qualified Foreign Institutional Investors (RQFII) on Friday, formally giving a green light to investment of overseas RMB funds in mainland securities markets.The move is expected to widen the investment channel of overseas RMB funds and add new momentum to the country's bid to make the RMB an international currency.Hong Kong subsidiaries of fund management companies and securities firms can use RMB funds raised in Hong Kong to invest in mainland securities within a permitted quota, according to the rules jointly released by the China Securities Regulatory Commission (CSRC), the People's Bank of China and the State Administration of Foreign Exchange.The total investment quota of RQFII pilot programs is set at around 20 billion yuan (3.15 billion U.S. dollars), according to the rules.To control risks, qualified investors should invest no less than 80 percent of the RMB funds they raised in fixed-income securities, while investment in stocks and equity funds should account for no more than 20 percent.The CSRC will join other related departments to study the possibility of further expanding the trial program after its launch, said a CSRC official who declined to be identified.The launch of the RQFII will open another significant channel for overseas RMB funds to flow back into the country, said the CSRC official.It will also help diversify investment products for overseas RMB funds and facilitate off-shore RMB business, the official said.The RMB is not fully convertible under the capital account but China has stepped up efforts to make the currency more international over the past few years.The government has encouraged the use of the RMB in cross-border trade and investment settlement and approved foreign direct investment in overseas RMB funds obtained overseas.It also allowed Hong Kong to establish an offshore yuan market and has expanded trade settlement agreements and currency swaps to create more channels for the yuan to circulate outside the mainland.

OTTAWA, Oct. 3 (Xinhua) -- Many friends and colleagues of Canadian scientist Ralph Steinman reacted with shock when they learned on Monday that Steinman won the Nobel Prize for Medicine and Physiology three days after he died.Since 1974, Nobel Prizes are no longer awarded posthumously, but the Nobel Prize committee said that it had made its choice before Steinman's death.Many of Steinman's friends and colleagues said that they learned of Steinman's death at the same time that they learned of his Nobel Prize, which was awarded for a discovery Steinman made in 1973.Steinman, 68, discovered dendritic cells, which help regulate adaptive immunity, which purges invading microorganisms from the body. Dendritic cells activate T cells, which "remember" the DNA sequence of invading organisms and protect the body from later infections from the same disease."Their work has opened up new avenues for the development of prevention and therapy against infections, cancer and inflammatory disease," the citation said.Monday, the Nobel Committee defended its decision to award the prize to Steinman. "The decision to award the Nobel Prize to Ralph Steinman was made in good faith, based on the assumption that the Nobel Laureate was alive," the foundation said in a statement."The Nobel Foundation thus believes that what has occurred is more reminiscent of the example in the statutes concerning a person who has been named as a Nobel Laureate and has died before the actual Nobel Prize Award Ceremony."It is still unclear who will pick up Steinman's prize at the award ceremony later this year.Steinman, a cell biologist at Rockefeller University in New York City, died of pancreatic cancer on Friday. For more than four years, he had used his own immune therapy discoveries to extend his life."The news is bittersweet, as we also learned this morning from Ralph's family that he passed a few days ago," Rockefeller University President Marc Tessier-Lavigne said in a statement."We are all so touched that our father's many years of hard work are being recognized with a Nobel Prize," Steinman's daughter, Alexis, said in the statement. "He devoted his life to his work and his family, and he would be truly honored."Steinman's heirs will share the 1.5-million U.S. dollar prize with American genetics professor Bruce Beutler and French scientist Jules Hoffmann.Dr. Beutler is professor of genetics and immunology at The Scripps Research Institute in La Jolla, California. Dr. Hoffmann headed a research laboratory in Strasbourg, France, between 1974 and 2009 and served as president of the French National Academy of Sciences between 2007 and 2008."Ralph worked right up until last week," said Michel Nussenzweig, a collaborator of Steinman's at Rockefeller University. "His dream was to use his discovery to cure cancer and infectious diseases like HIV and tuberculosis. It's a dream that's pretty close."Steinman was born in 1943 in Montreal, Canada's second largest city, and studied chemistry and biology at McGill University in his hometown before receiving an MD from Harvard Medical School in Boston in 1968. He joined Rockefeller University in 1970 as a postdoctoral fellow."He was diagnosed with pancreatic cancer four years ago, and his life was extended using a dendritic-cell based immunotherapy of his own design," the university said in a statement.In a statement, Canadian Prime Minister Stephen Harper lauded the three winners of the Nobel for medicine and called the award " a fitting final tribute" to Steinman's life's work."Dr. Steinman shall be honored for all time with this achievement," Harper said. "Canadians will mourn his loss."